Choosing the Right Packaging to Safeguard Pharmaceutical Products Against Photodegradation

Protecting pharmaceutical products from the harmful effects of light exposure is an essential consideration in drug development. Photodegradation can lead to potency loss, impurity formation, and color changes—compromising product quality, safety, and regulatory compliance. The container-closure system serves as the first line of defense against photolytic damage. Therefore, selecting a suitable container for photostability protection is a critical step guided by scientific, regulatory, and material-specific criteria. This tutorial outlines best practices for evaluating and selecting packaging systems to meet the light protection needs of drug products, in accordance with ICH Q1B and global standards.

1. Importance of Container Selection in Photostability

Why Packaging Matters:

• Light exposure can initiate photochemical reactions that degrade APIs or excipients
• The wrong container may transmit harmful wavelengths, accelerating degradation
• Regulatory approval may be denied or delayed without validated packaging protection

ICH Q1B Guidance:

• Photostability studies must include testing in the final or proposed market container
• Results help determine labeling needs (e.g., “Protect from light”) and storage conditions
• Both drug substance and product containers must be evaluated when applicable

2. Types of Containers Used for Photostability Protection

Common Primary Containers:

• Glass Vials and Bottles: Amber, clear, or flint glass with varying light transmittance
• Plastic Containers: Polyethylene (PE), polypropylene (PP), polyvinyl chloride (PVC), polyethylene terephthalate (PET), often with additives or colorants
• Blister Packs: PVC, PVDC, Aclar®, and aluminum-based films for oral dosage forms
• Syringes and Cartridges: Made from glass or plastic; require validation of light barrier properties

Secondary Packaging Considerations:

• Outer cartons, inserts, and foil overwraps add a second level of protection
• Regulatory bodies may accept light protection achieved via secondary packaging only if validated

3. Mechanisms of Light Protection by Packaging

1. UV Absorption:

• Amber glass and UV-stabilized plastics absorb light in the 200–450 nm range
• Protects against photodegradation caused by UVB and UVA light

2. Light Scattering and Reflection:

• Opaque containers scatter or reflect incident light, reducing internal transmission
• Useful for formulations sensitive to visible light (>450 nm)

3. Pigment-Based Shielding:

• Incorporating titanium dioxide or iron oxide pigments blocks light penetration in plastic containers
• Colorants must be biocompatible and non-leachable

4. Evaluating Light Transmission Through Packaging

Spectral Transmission Testing:

• Use UV-Vis spectrophotometer to measure light transmittance through container walls
• Focus on 290–700 nm range, with particular attention to 320–400 nm (UV-A) and 400–500 nm (visible)
• Amber glass typically transmits 80%

Labeling Thresholds Based on Transmittance:

• Low transmission (<10%): May not require “Protect from light” label if supported by stability data
• Moderate transmission (10–50%): Likely to require protective labeling and/or secondary packaging
• High transmission (>50%): Not suitable for light-sensitive products without additional protection

Testing Under ICH Q1B Conditions:

• Expose product in final container to 1.2 million lux hours and 200 Wh/m² UV
• Compare product degradation in transparent vs. opaque or amber containers
• Evaluate visual and chemical changes (e.g., assay, impurities, color shift)

5. Packaging Material Comparison: Strengths and Limitations

6. Packaging Design Considerations for Light-Sensitive Drugs

Form-Factor-Based Selection:

• Injectables: Amber vials or prefilled syringes with UV filters
• Oral solutions: Opaque or amber PET bottles with light-resistant labels
• Solid dosage: Aluminum-aluminum blisters or foil-pouched bottles

Additional Protective Measures:

• Light-blocking sleeves for infusion bags or IV tubing
• Colored shrink wraps or over-labels to block specific wavelengths
• Carton designs with UV-filter coatings or reflective layers

7. Regulatory Expectations and Documentation

Documentation in Submission Dossiers:

• Module 3.2.P.2: Packaging selection justification based on stability data
• Module 3.2.P.7: Description of container-closure materials and configurations
• Module 3.2.P.8.3: Photostability test results under ICH Q1B conditions

Regulatory Review Trends:

• FDA and EMA may request additional studies if container is not inherently light-protective
• WHO PQ prefers performance-based validation over theoretical packaging claims
• Post-approval changes to container require bridging data and new validation

8. Case Study: Choosing Packaging for a Light-Sensitive Oral Solution

Background:

Multivitamin oral liquid with riboflavin and folic acid—both known to degrade under light exposure.

Options Evaluated:

• Clear PET bottle + foil overwrap
• Amber PET bottle without carton
• Opaque HDPE bottle with carton

Findings:

• Clear PET showed >20% potency loss after ICH Q1B exposure
• Amber PET contained degradation to <5%, but label faded under visible light
• Opaque HDPE + carton showed <1% loss and excellent color retention

Final Decision:

• Selected opaque HDPE bottle with protective carton
• Added “Protect from light. Store in original package” to labeling
• Results documented in Module 3.2.P.8.3 and packaging strategy justified in 3.2.P.2

9. SOPs and Validation Tools

Available from Pharma SOP:

• Photostability Container Evaluation SOP
• Light Transmission Testing Protocol Template
• Packaging Qualification Form for Photostability Claims
• Container Risk Assessment Tool (ICH Q1B Aligned)

For more implementation resources, visit Stability Studies.

Conclusion

Container selection is a pivotal component of photostability management in pharmaceutical development. By understanding light transmission properties, evaluating degradation risks, and validating container performance under ICH Q1B exposure conditions, formulators can ensure product quality, regulatory acceptance, and patient safety. Whether choosing amber glass, pigmented polymers, or multilayer blisters, the packaging must be science-driven, risk-informed, and thoroughly documented to support long-term product success.